Merck reported strong quarterly performance with revenue and non-GAAP EPS exceeding expectations, and the company raised its full-year guidance. The positive outlook on key products like KEYTRUDA and strategic growth initiatives further bolster investor confidence. These factors are likely to positively influence the stock in the short term.

[1]